Although the name Cassio Audi rings many bells resonating with success in the Brazilian finance industry, he is also a talented musician whose roots can be traced to the emergence of traditional rock metal music groups in Brazil. During the early days when he was searching for a meaningful career, he prominently featured in many bands. Many people who knew him well at the time say that he is an energetic and multifaceted personality who demonstrates the same zeal he had in music in other businesses he is involved in
Amongst the top music bands, he played with in the 1980s are groups such as Soldiers of Sunrise and Killera Sword bands. He was often a drummer, but occasionally he would play other instruments. Between 1985 and 1989 Audi was quite instrumental in giving many fledgling bands a sense of purpose and direction. All around the world, heavy metal music lovers readily recognize the name of Audi. He inspired and popularized the music genre in Brazil during the period when he first came to the attention of international metal music fans as a drummer for Viper, a Brazilian band.
He was a leader in expanding the scene of heavy metal music in the entire region of Latin America. The Viper was a band strongly influenced by the British heavy metal music groups of the 1970s and early 80s. Although all the band members were teenagers, Cassio Audi always played a key role in the evolution of the groups. In particular, his energy and commitment to playing music made the Viper to enjoy international recognition and success until 1989 when Audi left the group. In 1985, he contributed a lot to the first demo recording known as The Killera Sword, which was followed by 1987 Viper’s debut album called Soldier of Sunrise.
Investment banking entails making sustainable investments for clients. Cassio Audi is a financial expert who makes these investments for clients. His 23 years of experience in the industry places him on good standing with potential clients. His career has seen him work in various fields including IPO, productivity improvement, monitoring and assessment and change management.
Cassio Audi started working in real estate with a private company in Brazil from September 2013. At this company, he is responsible for asset management, investor matters and fundraising. Before joining his current company, he worked at Rossi Commercial as a senior financial officer. Prior to joining Rossi, he worked at Brascan Brasil Real Estate for two years from June 2006 to Mid August 2008. He had worked for SAP at HR department leader between March and August of 2008. Audi also served as senior analyst at FP&E as well as Gillette.
Cassio went to Pontifícia Universidade Católica de São Paulo where he got his Bachelor’s degree between 1989 and 1994. After the first degree Cassio decided to go back to school five years later to get an MBA between 1999 and 2000 at Universidade de São Paulo. Audi skill set include strategic planning, project management, entrepreneurship, project planning, corporate finance, equities management, mergers and acquisitions and restructuring.
Audi is of Brazilian upbringing and heritage. He can speak English with a native fluency and proficiency. He is also proficient in Spanish like most Brazilians
There are so many people who struggle on finding out what kind of treatments are best for you. Countless people and even physicians sometimes need that instant help in order to know what a person needs for their body and health. With the help of the Cancer Treatment Center of America working towards fixing this with new technology, they are definitely finding one solution one step at a time. They recently have released the Clinical Pathways program that is going to change how doctors work together with their patients in terms of what to do with their cancer.
According to Wikipedia, Clinical Pathways is a new solution that is going to update everybody in real-time what a patient needs based on their current state of health. Things like how their health is coping at the moment is going to be measured to ensure that any type of recommendations given is perfect for their health. All the cancer is tough to deal with, and Clinical Pathways is going to give physicians up to date knowledge on what to remember regarding what is best for their patients. There are custom treatment regimens available, comparisons between the options, alongside what knowing what is safe and most efficient for them. There is also a quick look at what is most cost-effective to think about regarding their health.
This Cancer Treatment Center of America is mainly focused on providing adults with solutions and treatments for their cancer. They aim to provide an integrative approach to combine powerful solutions for overcoming all kinds of cancer with advanced treatments, radiation, chemotherapy, and other forms of therapy to help adults overcome their biggest obstacles with their health. It’s important that they stay on their toes to help provide their patients with results, and they do it every day in all of their hospitals nationwide.
For more information follow Cancer Treatment Centers of America on Facebook.
If you are unfamiliar with the name Clay Siegall then you’re probably not alone, this individual has done major things in cancer research throughout the years and is well respected among his peers. He’s the author of 70 publications, has a Ph.D inGenetics, (BS) in Zoology, and known to many as a scientist. Dr. Clay Siegall is CEO and President of Biotech Company Seattle Genetics. Seattle Genetics of Bothell, Washington specializes in the development and commercialization of antibody based therapies and is one of the top companies in the world for doing this. Dr. Siegall has built a sturdy foundation for the company ever since it’s inception in the late 90’s. Dr. Siegall’s role span into capital raising as well as he has secured over $1.2 Billion through private and public financing.
The company’s flagship drug ADCETRIS is currently being used in over 65 countries worldwide thanks to Dr. Siegall’s savvy business sense. The business sense has allowed him to enter the company’s (ADC) Antibody Drug Conjugates into multiple licensed agreements with some really huge industry names which has resulted growth earning of up to $225 Million in 2015 for Canada and the U.S. Future projections are looking to be around $255-$275 Million for 2016. Forbes Magazine has ranked Seattle Genetics asone of the fastest growing companies in the nation as well for last year. There are numerous drugs already in the pipeline and advancement stages which will result in another hiring blitz well into the future.
The success of these innovative antibody drug conjugates is that they deliver cell killing agents straight into cancerous cells while sparing non-targeted cells. The treatments are far more advanced than treatments of the past which resulted in nasty side effects. Dr. Clay Siegall’s winning strategy is now the blueprint of success in this ever changing field of work and Seattle Genetics is standing at the apex of the industry for doing so.